XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > XORTX Is Definitely Oversold

<< Previous

Bullboard Posts

Next >>

Post by NLMooseon Oct 14, 2020 11:38am

150 Views

Post# 31714008

XORTX Is Definitely Oversold

While the Food and Drug Adminstration are imprssed with XORTX' preclinical trials, looks like investors are not happy as the stock is getting close to record low levels.

You think that stocks involving companies whom are developing COVID-19 treatments would be seeing increases in share prices, particuarly XORTX, not fall to record low levels.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market